ABOUT US

Welcome to EpiEndo Pharmaceuticals

EpiEndo is a clinical stage pharmaceutical company developing a proprietary portfolio of drugs to address the huge global burden of chronic respiratory diseases. Over more than a decade our research into the disease etiology of chronic obstructive pulmonary disease (COPD) has led to our unique insights in inflammatory processes.

Our new class of orally-available macrolide candidate NCEs show promise as first-in-class disease-modifying therapeutics for COPD. Our lead compound is a non-antibiotic analogue of azithromycin which modulates inflammation through strengthening the lung epithelium. We are actively exploring additional potential applications for post COVID-19 treatment, where the established anti-inflammatory properties of our technology may be of value.

OUR TEAM

 

We operate an agile business with an experienced core team based across Iceland, Sweden, Germany and the UK, supported by global key opinion leaders and pulmonary specialists, with contractors and consultants filling other key functions.

Executive Leadership

Maria_Bech.jpg

Maria Bech, MSc

CEO

Ginny Norris, PhD

Ginny Norris, PhD

CMO

Michael_Parnham.jpg

Mike Parnham, PhD

CSO

Chief Innovation Officer

Jennifer_Krickert.jpg

Director of Research

Board

Clive_Page.jpg

Prof Clive Page, OBE, PhD

Chairman of the Board

Magnús Magnússon, MSc

Board Member

Robert Helgason

Board Member

Carl Johan Spak, PhD

Board Member

Ivar Gudjonsson

Ívar Guðjónsson, MBA

Board Member

Hilmar Bragi Janusson, PhD

Board Member

Senior Advisors

Prof Peter Barnes, FRS

SAB

Olafur Baldursson, MD, PhD

Director

Prof Dave Singh, MD

SAB

Prof Thorarinn Gudjonsson

SAB